

Global Neurotransmitter Endogenous Regulation Platform Market Research Report 2026(Status and Outlook)

<https://marketpublishers.com/r/GB70623AA106EN.html>

Date: February 2026

Pages: 115

Price: US\$ 2,980.00 (Single User License)

ID: GB70623AA106EN

Abstracts

The neurotransmitter endogenous regulation platform is a system built on neuroscience and molecular biotechnology, which is used to regulate the synthesis, release, reuptake and metabolism of neurotransmitters in the body, thereby maintaining the functional balance of the nervous system. This platform usually combines technologies such as gene editing, small molecule intervention or targeted vectors to accurately regulate the endogenous levels of key neurotransmitters such as dopamine, glutamate, and 5-hydroxytryptamine, and is widely used in the study of the mechanisms of neuropsychiatric diseases and the development of individualized intervention strategies.

The global Neurotransmitter Endogenous Regulation Platform market size was estimated at USD 1301.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 12.30% during the forecast period.

This report offers a comprehensive and in-depth analysis of the global Neurotransmitter Endogenous Regulation Platform market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.

The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.

A significant focus of this report lies in the competitive landscape of the global

Neurotransmitter Endogenous Regulation Platform market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.

In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Neurotransmitter Endogenous Regulation Platform market.

Global Neurotransmitter Endogenous Regulation Platform Market: Market Segmentation Analysis

This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.

A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.

Key Company

Neurocrine Biosciences
Intra-Cellular Therapies
BrainsWay
BlackThorn Therapeutics
MindMed
Voyager Therapeutics
COMPASS Pathways
Neuroelectronics
Cervel Therapeutics
Axsome Therapeutics
Atai Life Sciences
Neumora Therapeutics

Alto Neuroscience
An Ranfei

Market Segmentation (by Type)

Chemical Molecular Regulation Platform
Bioengineering Regulation Platform

Market Segmentation (by Application)

Hospital
Clinic
Others

Geographic Segmentation

North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Neurotransmitter Endogenous Regulation Platform Market
Overview of the regional outlook of the Neurotransmitter Endogenous Regulation Platform Market:

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Neurotransmitter Endogenous Regulation Platform Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Neurotransmitter Endogenous Regulation Platform, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.

Chapter 13 is the main points and conclusions of the report.

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

- 1.1 Market Definition and Statistical Scope of Neurotransmitter Endogenous Regulation Platform
- 1.2 Key Market Segments
 - 1.2.1 Neurotransmitter Endogenous Regulation Platform Segment by Type
 - 1.2.2 Neurotransmitter Endogenous Regulation Platform Segment by Application
- 1.3 Methodology & Sources of Information
 - 1.3.1 Research Methodology
 - 1.3.2 Research Process
 - 1.3.3 Market Breakdown and Data Triangulation
 - 1.3.4 Base Year
 - 1.3.5 Report Assumptions & Caveats

2 NEUROTRANSMITTER ENDOGENOUS REGULATION PLATFORM MARKET OVERVIEW

- 2.1 Global Market Overview
- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region

3 NEUROTRANSMITTER ENDOGENOUS REGULATION PLATFORM MARKET COMPETITIVE LANDSCAPE

- 3.1 Company Assessment Quadrant
- 3.2 Global Neurotransmitter Endogenous Regulation Platform Product Life Cycle
- 3.3 Global Neurotransmitter Endogenous Regulation Platform Revenue Market Share by Company (2020-2025)
- 3.4 Neurotransmitter Endogenous Regulation Platform Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.5 Headquarters, Areas Served, and Product Types of Major Players
- 3.6 Neurotransmitter Endogenous Regulation Platform Market Competitive Situation and Trends
 - 3.6.1 Neurotransmitter Endogenous Regulation Platform Market Concentration Rate
 - 3.6.2 Global 5 and 10 Largest Neurotransmitter Endogenous Regulation Platform Players Market Share by Revenue
 - 3.6.3 Mergers & Acquisitions, Expansion

4 NEUROTRANSMITTER ENDOGENOUS REGULATION PLATFORM VALUE CHAIN ANALYSIS

- 4.1 Neurotransmitter Endogenous Regulation Platform Value Chain Analysis
- 4.2 Midstream Market Analysis
- 4.3 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF NEUROTRANSMITTER ENDOGENOUS REGULATION PLATFORM MARKET

- 5.1 Key Development Trends
- 5.2 Driving Factors
- 5.3 Market Challenges
- 5.4 Industry News
 - 5.4.1 New Product Developments
 - 5.4.2 Mergers & Acquisitions
 - 5.4.3 Expansions
 - 5.4.4 Collaboration/Supply Contracts
- 5.5 PEST Analysis
 - 5.5.1 Industry Policies Analysis
 - 5.5.2 Economic Environment Analysis
 - 5.5.3 Social Environment Analysis
 - 5.5.4 Technological Environment Analysis
- 5.6 Global Neurotransmitter Endogenous Regulation Platform Market Porter's Five Forces Analysis

6 NEUROTRANSMITTER ENDOGENOUS REGULATION PLATFORM MARKET SEGMENTATION BY TYPE

- 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
- 6.2 Global Neurotransmitter Endogenous Regulation Platform Market by Type (2020-2025)
- 6.3 Global Neurotransmitter Endogenous Regulation Platform Market Size Growth Rate by Type (2021-2025)

7 NEUROTRANSMITTER ENDOGENOUS REGULATION PLATFORM MARKET SEGMENTATION BY APPLICATION

- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Neurotransmitter Endogenous Regulation Platform Market Size (M USD) by Application (2020-2025)
- 7.3 Global Neurotransmitter Endogenous Regulation Platform Market Size Growth Rate by Application (2021-2025)

8 NEUROTRANSMITTER ENDOGENOUS REGULATION PLATFORM MARKET SEGMENTATION BY REGION

- 8.1 Global Neurotransmitter Endogenous Regulation Platform Market Size by Region
 - 8.1.1 Global Neurotransmitter Endogenous Regulation Platform Market Size by Region
 - 8.1.2 Global Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Region
- 8.2 North America
 - 8.2.1 North America Neurotransmitter Endogenous Regulation Platform Market Size by Country
 - 8.2.2 U.S.
 - 8.2.3 Canada
 - 8.2.4 Mexico
- 8.3 Europe
 - 8.3.1 Europe Neurotransmitter Endogenous Regulation Platform Market Size by Country
 - 8.3.2 Germany
 - 8.3.3 France
 - 8.3.4 U.K.
 - 8.3.5 Italy
 - 8.3.6 Spain
- 8.4 Asia Pacific
 - 8.4.1 Asia Pacific Neurotransmitter Endogenous Regulation Platform Market Size by Region
 - 8.4.2 China
 - 8.4.3 Japan
 - 8.4.4 South Korea
 - 8.4.5 India
 - 8.4.6 Southeast Asia
- 8.5 South America
 - 8.5.1 South America Neurotransmitter Endogenous Regulation Platform Market Size by Country
 - 8.5.2 Brazil

8.5.3 Argentina

8.5.4 Columbia

8.6 Middle East and Africa

8.6.1 Middle East and Africa Neurotransmitter Endogenous Regulation Platform

Market Size by Region

8.6.2 Saudi Arabia

8.6.3 UAE

8.6.4 Egypt

8.6.5 Nigeria

8.6.6 South Africa

9 KEY COMPANIES PROFILE

9.1 Neurocrine Biosciences

9.1.1 Neurocrine Biosciences Basic Information

9.1.2 Neurocrine Biosciences Neurotransmitter Endogenous Regulation Platform

Product Overview

9.1.3 Neurocrine Biosciences Neurotransmitter Endogenous Regulation Platform

Product Market Performance

9.1.4 Neurocrine Biosciences SWOT Analysis

9.1.5 Neurocrine Biosciences Business Overview

9.1.6 Neurocrine Biosciences Recent Developments

9.2 Intra-Cellular Therapies

9.2.1 Intra-Cellular Therapies Basic Information

9.2.2 Intra-Cellular Therapies Neurotransmitter Endogenous Regulation Platform

Product Overview

9.2.3 Intra-Cellular Therapies Neurotransmitter Endogenous Regulation Platform

Product Market Performance

9.2.4 Intra-Cellular Therapies SWOT Analysis

9.2.5 Intra-Cellular Therapies Business Overview

9.2.6 Intra-Cellular Therapies Recent Developments

9.3 BrainsWay

9.3.1 BrainsWay Basic Information

9.3.2 BrainsWay Neurotransmitter Endogenous Regulation Platform Product Overview

9.3.3 BrainsWay Neurotransmitter Endogenous Regulation Platform Product Market

Performance

9.3.4 BrainsWay SWOT Analysis

9.3.5 BrainsWay Business Overview

9.3.6 BrainsWay Recent Developments

9.4 BlackThorn Therapeutics

9.4.1 BlackThorn Therapeutics Basic Information

9.4.2 BlackThorn Therapeutics Neurotransmitter Endogenous Regulation Platform Product Overview

9.4.3 BlackThorn Therapeutics Neurotransmitter Endogenous Regulation Platform Product Market Performance

9.4.4 BlackThorn Therapeutics Business Overview

9.4.5 BlackThorn Therapeutics Recent Developments

9.5 MindMed

9.5.1 MindMed Basic Information

9.5.2 MindMed Neurotransmitter Endogenous Regulation Platform Product Overview

9.5.3 MindMed Neurotransmitter Endogenous Regulation Platform Product Market Performance

9.5.4 MindMed Business Overview

9.5.5 MindMed Recent Developments

9.6 Voyager Therapeutics

9.6.1 Voyager Therapeutics Basic Information

9.6.2 Voyager Therapeutics Neurotransmitter Endogenous Regulation Platform Product Overview

9.6.3 Voyager Therapeutics Neurotransmitter Endogenous Regulation Platform Product Market Performance

9.6.4 Voyager Therapeutics Business Overview

9.6.5 Voyager Therapeutics Recent Developments

9.7 COMPASS Pathways

9.7.1 COMPASS Pathways Basic Information

9.7.2 COMPASS Pathways Neurotransmitter Endogenous Regulation Platform Product Overview

9.7.3 COMPASS Pathways Neurotransmitter Endogenous Regulation Platform Product Market Performance

9.7.4 COMPASS Pathways Business Overview

9.7.5 COMPASS Pathways Recent Developments

9.8 Neuroelectrics

9.8.1 Neuroelectrics Basic Information

9.8.2 Neuroelectrics Neurotransmitter Endogenous Regulation Platform Product Overview

9.8.3 Neuroelectrics Neurotransmitter Endogenous Regulation Platform Product Market Performance

9.8.4 Neuroelectrics Business Overview

9.8.5 Neuroelectrics Recent Developments

9.9 Cervel Therapeutics

9.9.1 Cervel Therapeutics Basic Information

9.9.2 Cervel Therapeutics Neurotransmitter Endogenous Regulation Platform Product Overview

9.9.3 Cervel Therapeutics Neurotransmitter Endogenous Regulation Platform Product Market Performance

9.9.4 Cervel Therapeutics Business Overview

9.9.5 Cervel Therapeutics Recent Developments

9.10 Axsome Therapeutics

9.10.1 Axsome Therapeutics Basic Information

9.10.2 Axsome Therapeutics Neurotransmitter Endogenous Regulation Platform Product Overview

9.10.3 Axsome Therapeutics Neurotransmitter Endogenous Regulation Platform Product Market Performance

9.10.4 Axsome Therapeutics Business Overview

9.10.5 Axsome Therapeutics Recent Developments

9.11 Atai Life Sciences

9.11.1 Atai Life Sciences Basic Information

9.11.2 Atai Life Sciences Neurotransmitter Endogenous Regulation Platform Product Overview

9.11.3 Atai Life Sciences Neurotransmitter Endogenous Regulation Platform Product Market Performance

9.11.4 Atai Life Sciences Business Overview

9.11.5 Atai Life Sciences Recent Developments

9.12 Neumora Therapeutics

9.12.1 Neumora Therapeutics Basic Information

9.12.2 Neumora Therapeutics Neurotransmitter Endogenous Regulation Platform Product Overview

9.12.3 Neumora Therapeutics Neurotransmitter Endogenous Regulation Platform Product Market Performance

9.12.4 Neumora Therapeutics Business Overview

9.12.5 Neumora Therapeutics Recent Developments

9.13 Alto Neuroscience

9.13.1 Alto Neuroscience Basic Information

9.13.2 Alto Neuroscience Neurotransmitter Endogenous Regulation Platform Product Overview

9.13.3 Alto Neuroscience Neurotransmitter Endogenous Regulation Platform Product Market Performance

9.13.4 Alto Neuroscience Business Overview

9.13.5 Alto Neuroscience Recent Developments

9.14 An Ranfei

9.14.1 An Ranfei Basic Information

9.14.2 An Ranfei Neurotransmitter Endogenous Regulation Platform Product Overview

9.14.3 An Ranfei Neurotransmitter Endogenous Regulation Platform Product Market Performance

9.14.4 An Ranfei Business Overview

9.14.5 An Ranfei Recent Developments

10 NEUROTRANSMITTER ENDOGENOUS REGULATION PLATFORM MARKET FORECAST BY REGION

10.1 Global Neurotransmitter Endogenous Regulation Platform Market Size Forecast

10.2 Global Neurotransmitter Endogenous Regulation Platform Market Forecast by Region

10.2.1 North America Market Size Forecast by Country

10.2.2 Europe Neurotransmitter Endogenous Regulation Platform Market Size Forecast by Country

10.2.3 Asia Pacific Neurotransmitter Endogenous Regulation Platform Market Size Forecast by Region

10.2.4 South America Neurotransmitter Endogenous Regulation Platform Market Size Forecast by Country

10.2.5 Middle East and Africa Forecasted Sales of Neurotransmitter Endogenous Regulation Platform by Country

11 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)

11.1 Global Neurotransmitter Endogenous Regulation Platform Market Forecast by Type (2026-2035)

11.1.1 Global Neurotransmitter Endogenous Regulation Platform Market Size Forecast by Type (2026-2035)

11.2 Global Neurotransmitter Endogenous Regulation Platform Market Forecast by Application (2026-2035)

11.2.1 Global Neurotransmitter Endogenous Regulation Platform Market Size (M USD) Forecast by Application (2026-2035)

12 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

- Table 1. Introduction of the Type
- Table 2. Introduction of the Application
- Table 3. Global Neurotransmitter Endogenous Regulation Platform Market Size by Type (M USD)
- Table 4. Global Neurotransmitter Endogenous Regulation Platform Market Size by Application
- Table 5. Neurotransmitter Endogenous Regulation Platform Market Size Comparison by Region (M USD)
- Table 6. Global Neurotransmitter Endogenous Regulation Platform Revenue (M USD) by Company (2020-2025)
- Table 7. Global Neurotransmitter Endogenous Regulation Platform Revenue Share by Company (2020-2025)
- Table 8. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurotransmitter Endogenous Regulation Platform as of 2025)
- Table 9. Headquarters, Areas Served, and Product Types of Major Players
- Table 10. Product Type of Major Players
- Table 11. Global Neurotransmitter Endogenous Regulation Platform Company Market Concentration Ratio (CR5 and HHI)
- Table 12. Mergers & Acquisitions, Expansion Plans
- Table 13. Midstream Market Analysis
- Table 14. Downstream Customer Analysis
- Table 15. Key Development Trends
- Table 16. Driving Factors
- Table 17. Neurotransmitter Endogenous Regulation Platform Market Challenges
- Table 18. Goldman Sachs' forecast real GDP growth rate for 2024-2026
- Table 19. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
- Table 20. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
- Table 21. Global Neurotransmitter Endogenous Regulation Platform Market Size by Type (M USD)
- Table 22. Global Neurotransmitter Endogenous Regulation Platform Market Size (M USD) by Type (2020-2025)
- Table 23. Global Neurotransmitter Endogenous Regulation Platform Market Share by Type (2020-2025)
- Table 24. Global Neurotransmitter Endogenous Regulation Platform Market Size Growth Rate by Type (2021-2025)

Table 25. Global Neurotransmitter Endogenous Regulation Platform Market Size by Application

Table 26. Global Neurotransmitter Endogenous Regulation Platform Market Size by Application (2020-2025) & (M USD)

Table 27. Global Neurotransmitter Endogenous Regulation Platform Market Share by Application (2020-2025)

Table 28. Global Neurotransmitter Endogenous Regulation Platform Market Size Growth Rate by Application (2021-2025)

Table 29. Global Neurotransmitter Endogenous Regulation Platform Market Size by Region (2020-2025) & (M USD)

Table 30. Global Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Region (2020-2025)

Table 31. North America Neurotransmitter Endogenous Regulation Platform Market Size by Country (2020-2025) & (M USD)

Table 32. Europe Neurotransmitter Endogenous Regulation Platform Market Size by Country (2020-2025) & (M USD)

Table 33. Asia Pacific Neurotransmitter Endogenous Regulation Platform Market Size by Region (2020-2025) & (M USD)

Table 34. South America Neurotransmitter Endogenous Regulation Platform Market Size by Country (2020-2025) & (M USD)

Table 35. Middle East and Africa Neurotransmitter Endogenous Regulation Platform Market Size by Region (2020-2025) & (M USD)

Table 36. Neurocrine Biosciences Basic Information

Table 37. Neurocrine Biosciences Neurotransmitter Endogenous Regulation Platform Product Overview

Table 38. Neurocrine Biosciences Neurotransmitter Endogenous Regulation Platform Revenue (M USD) and Gross Margin (2020-2025)

Table 39. Neurocrine Biosciences SWOT Analysis

Table 40. Neurocrine Biosciences Business Overview

Table 41. Neurocrine Biosciences Recent Developments

Table 42. Intra-Cellular Therapies Basic Information

Table 43. Intra-Cellular Therapies Neurotransmitter Endogenous Regulation Platform Product Overview

Table 44. Intra-Cellular Therapies Neurotransmitter Endogenous Regulation Platform Revenue (M USD) and Gross Margin (2020-2025)

Table 45. Intra-Cellular Therapies SWOT Analysis

Table 46. Intra-Cellular Therapies Business Overview

Table 47. Intra-Cellular Therapies Recent Developments

Table 48. BrainsWay Basic Information

Table 49. BrainsWay Neurotransmitter Endogenous Regulation Platform Product Overview

Table 50. BrainsWay Neurotransmitter Endogenous Regulation Platform Revenue (M USD) and Gross Margin (2020-2025)

Table 51. BrainsWay SWOT Analysis

Table 52. BrainsWay Business Overview

Table 53. BrainsWay Recent Developments

Table 54. BlackThorn Therapeutics Basic Information

Table 55. BlackThorn Therapeutics Neurotransmitter Endogenous Regulation Platform Product Overview

Table 56. BlackThorn Therapeutics Neurotransmitter Endogenous Regulation Platform Revenue (M USD) and Gross Margin (2020-2025)

Table 57. BlackThorn Therapeutics Business Overview

Table 58. BlackThorn Therapeutics Recent Developments

Table 59. MindMed Basic Information

Table 60. MindMed Neurotransmitter Endogenous Regulation Platform Product Overview

Table 61. MindMed Neurotransmitter Endogenous Regulation Platform Revenue (M USD) and Gross Margin (2020-2025)

Table 62. MindMed Business Overview

Table 63. MindMed Recent Developments

Table 64. Voyager Therapeutics Basic Information

Table 65. Voyager Therapeutics Neurotransmitter Endogenous Regulation Platform Product Overview

Table 66. Voyager Therapeutics Neurotransmitter Endogenous Regulation Platform Revenue (M USD) and Gross Margin (2020-2025)

Table 67. Voyager Therapeutics Business Overview

Table 68. Voyager Therapeutics Recent Developments

Table 69. COMPASS Pathways Basic Information

Table 70. COMPASS Pathways Neurotransmitter Endogenous Regulation Platform Product Overview

Table 71. COMPASS Pathways Neurotransmitter Endogenous Regulation Platform Revenue (M USD) and Gross Margin (2020-2025)

Table 72. COMPASS Pathways Business Overview

Table 73. COMPASS Pathways Recent Developments

Table 74. Neuroelectrics Basic Information

Table 75. Neuroelectrics Neurotransmitter Endogenous Regulation Platform Product Overview

Table 76. Neuroelectrics Neurotransmitter Endogenous Regulation Platform Revenue

(M USD) and Gross Margin (2020-2025)

Table 77. Neuroelectrics Business Overview

Table 78. Neuroelectrics Recent Developments

Table 79. Cervel Therapeutics Basic Information

Table 80. Cervel Therapeutics Neurotransmitter Endogenous Regulation Platform Product Overview

Table 81. Cervel Therapeutics Neurotransmitter Endogenous Regulation Platform Revenue (M USD) and Gross Margin (2020-2025)

Table 82. Cervel Therapeutics Business Overview

Table 83. Cervel Therapeutics Recent Developments

Table 84. Axsome Therapeutics Basic Information

Table 85. Axsome Therapeutics Neurotransmitter Endogenous Regulation Platform Product Overview

Table 86. Axsome Therapeutics Neurotransmitter Endogenous Regulation Platform Revenue (M USD) and Gross Margin (2020-2025)

Table 87. Axsome Therapeutics Business Overview

Table 88. Axsome Therapeutics Recent Developments

Table 89. Atai Life Sciences Basic Information

Table 90. Atai Life Sciences Neurotransmitter Endogenous Regulation Platform Product Overview

Table 91. Atai Life Sciences Neurotransmitter Endogenous Regulation Platform Revenue (M USD) and Gross Margin (2020-2025)

Table 92. Atai Life Sciences Business Overview

Table 93. Atai Life Sciences Recent Developments

Table 94. Neumora Therapeutics Basic Information

Table 95. Neumora Therapeutics Neurotransmitter Endogenous Regulation Platform Product Overview

Table 96. Neumora Therapeutics Neurotransmitter Endogenous Regulation Platform Revenue (M USD) and Gross Margin (2020-2025)

Table 97. Neumora Therapeutics Business Overview

Table 98. Neumora Therapeutics Recent Developments

Table 99. Alto Neuroscience Basic Information

Table 100. Alto Neuroscience Neurotransmitter Endogenous Regulation Platform Product Overview

Table 101. Alto Neuroscience Neurotransmitter Endogenous Regulation Platform Revenue (M USD) and Gross Margin (2020-2025)

Table 102. Alto Neuroscience Business Overview

Table 103. Alto Neuroscience Recent Developments

Table 104. An Ranfei Basic Information

Table 105. An Ranfei Neurotransmitter Endogenous Regulation Platform Product Overview

Table 106. An Ranfei Neurotransmitter Endogenous Regulation Platform Revenue (M USD) and Gross Margin (2020-2025)

Table 107. An Ranfei Business Overview

Table 108. An Ranfei Recent Developments

Table 109. Global Neurotransmitter Endogenous Regulation Platform Market Size Forecast by Region (2026-2035) & (M USD)

Table 110. North America Neurotransmitter Endogenous Regulation Platform Market Size Forecast by Country (2026-2035) & (M USD)

Table 111. Europe Neurotransmitter Endogenous Regulation Platform Market Size Forecast by Country (2026-2035) & (M USD)

Table 112. Asia Pacific Neurotransmitter Endogenous Regulation Platform Market Size Forecast by Region (2026-2035) & (M USD)

Table 113. South America Neurotransmitter Endogenous Regulation Platform Market Size Forecast by Country (2026-2035) & (M USD)

Table 114. Middle East and Africa Neurotransmitter Endogenous Regulation Platform Market Size Forecast by Country (2026-2035) & (M USD)

Table 115. Global Neurotransmitter Endogenous Regulation Platform Market Size Forecast by Type (2026-2035) & (M USD)

Table 116. Global Neurotransmitter Endogenous Regulation Platform Market Size Forecast by Application (2026-2035) & (M USD)

List Of Figures

LIST OF FIGURES

- Figure 1. Industry Chain of Neurotransmitter Endogenous Regulation Platform
- Figure 2. Data Triangulation
- Figure 3. Key Caveats
- Figure 4. Global Neurotransmitter Endogenous Regulation Platform Market Size (M USD), 2025-2035
- Figure 5. Global Neurotransmitter Endogenous Regulation Platform Market Size (M USD) (2020-2035)
- Figure 6. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 7. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 8. Evaluation Matrix of Regional Market Development Potential
- Figure 9. Neurotransmitter Endogenous Regulation Platform Market Size by Country (M USD)
- Figure 10. Company Assessment Quadrant
- Figure 11. Global Neurotransmitter Endogenous Regulation Platform Product Life Cycle
- Figure 12. Global Neurotransmitter Endogenous Regulation Platform Revenue Share by Company in 2025
- Figure 13. Neurotransmitter Endogenous Regulation Platform Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
- Figure 14. The Global 5 and 10 Largest Players: Market Share by Neurotransmitter Endogenous Regulation Platform Revenue in 2025
- Figure 15. Value Chain Map of Neurotransmitter Endogenous Regulation Platform
- Figure 16. Global Neurotransmitter Endogenous Regulation Platform Market PEST Analysis
- Figure 17. Global Neurotransmitter Endogenous Regulation Platform Market Porter's Five Forces Analysis
- Figure 18. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 19. Global Neurotransmitter Endogenous Regulation Platform Market Share by Type
- Figure 20. Market Share of Neurotransmitter Endogenous Regulation Platform by Type (2020-2025)
- Figure 21. Global Neurotransmitter Endogenous Regulation Platform Market Size Growth Rate by Type (2021-2025)
- Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 23. Global Neurotransmitter Endogenous Regulation Platform Market Share by Application

Figure 24. Global Neurotransmitter Endogenous Regulation Platform Market Share by Application (2020-2025)

Figure 25. Global Neurotransmitter Endogenous Regulation Platform Market Share by Application in 2024

Figure 26. Global Neurotransmitter Endogenous Regulation Platform Market Size Growth Rate by Application (2021-2025)

Figure 27. Global Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Region (2020-2025)

Figure 28. North America Neurotransmitter Endogenous Regulation Platform Market Size and Growth Rate (2020-2025) & (M USD)

Figure 29. North America Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Country in 2024

Figure 30. U.S. Neurotransmitter Endogenous Regulation Platform Market Size and Growth Rate (2020-2025) & (M USD)

Figure 31. Canada Neurotransmitter Endogenous Regulation Platform Market Size (M USD) and Growth Rate (2020-2025)

Figure 32. Mexico Neurotransmitter Endogenous Regulation Platform Market Size (M USD) and Growth Rate (2020-2025)

Figure 33. Europe Neurotransmitter Endogenous Regulation Platform Market Size and Growth Rate (2020-2025) & (M USD)

Figure 34. Europe Neurotransmitter Endogenous Regulation Platform Market Share by Country in 2024

Figure 35. Germany Neurotransmitter Endogenous Regulation Platform Market Size and Growth Rate (2020-2025) & (M USD)

Figure 36. France Neurotransmitter Endogenous Regulation Platform Market Size and Growth Rate (2020-2025) & (M USD)

Figure 37. U.K. Neurotransmitter Endogenous Regulation Platform Market Size and Growth Rate (2020-2025) & (M USD)

Figure 38. Italy Neurotransmitter Endogenous Regulation Platform Market Size and Growth Rate (2020-2025) & (M USD)

Figure 39. Spain Neurotransmitter Endogenous Regulation Platform Market Size and Growth Rate (2020-2025) & (M USD)

Figure 40. Asia Pacific Neurotransmitter Endogenous Regulation Platform Market Size and Growth Rate (M USD)

Figure 41. Asia Pacific Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Region in 2024

Figure 42. China Neurotransmitter Endogenous Regulation Platform Market Size and Growth Rate (2020-2025) & (M USD)

Figure 43. Japan Neurotransmitter Endogenous Regulation Platform Market Size and

Growth Rate (2020-2025) & (M USD)

Figure 44. South Korea Neurotransmitter Endogenous Regulation Platform Market Size and Growth Rate (2020-2025) & (M USD)

Figure 45. India Neurotransmitter Endogenous Regulation Platform Market Size and Growth Rate (2020-2025) & (M USD)

Figure 46. Southeast Asia Neurotransmitter Endogenous Regulation Platform Market Size and Growth Rate (2020-2025) & (M USD)

Figure 47. South America Neurotransmitter Endogenous Regulation Platform Market Size and Growth Rate (M USD)

Figure 48. South America Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Country in 2024

Figure 49. Brazil Neurotransmitter Endogenous Regulation Platform Market Size and Growth Rate (2020-2025) & (M USD)

Figure 50. Argentina Neurotransmitter Endogenous Regulation Platform Market Size and Growth Rate (2020-2025) & (M USD)

Figure 51. Columbia Neurotransmitter Endogenous Regulation Platform Market Size and Growth Rate (2020-2025) & (M USD)

Figure 52. Middle East and Africa Neurotransmitter Endogenous Regulation Platform Market Size and Growth Rate (M USD)

Figure 53. Middle East and Africa Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Region in 2024

Figure 54. Saudi Arabia Neurotransmitter Endogenous Regulation Platform Market Size and Growth Rate (2020-2025) & (M USD)

Figure 55. UAE Neurotransmitter Endogenous Regulation Platform Market Size and Growth Rate (2020-2025) & (M USD)

Figure 56. Egypt Neurotransmitter Endogenous Regulation Platform Market Size and Growth Rate (2020-2025) & (M USD)

Figure 57. Nigeria Neurotransmitter Endogenous Regulation Platform Market Size and Growth Rate (2020-2025) & (M USD)

Figure 58. South Africa Neurotransmitter Endogenous Regulation Platform Market Size and Growth Rate (2020-2025) & (M USD)

Figure 59. Global Neurotransmitter Endogenous Regulation Platform Market Size Forecast by Value (2020-2035) & (M USD)

Figure 60. Global Neurotransmitter Endogenous Regulation Platform Market Share Forecast by Type (2026-2035)

Figure 61. Global Neurotransmitter Endogenous Regulation Platform Market Share Forecast by Application (2026-2035)

I would like to order

Product name: Global Neurotransmitter Endogenous Regulation Platform Market Research Report 2026(Status and Outlook)

Product link: <https://marketpublishers.com/r/GB70623AA106EN.html>

Price: US\$ 2,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GB70623AA106EN.html>